A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/ TGF-bRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors

作者全名："Xu, R-H.; Huiyan, L.; Zhao, H.; Wei, W.; Ma, D.; Yin, X.; Ni, Y.; Wang, Y.; Zhang, Y.; Zhou, J.; Pan, H.; Niu, Z.; Zhang, J.; Ren, H.; Kang, M.; Jia, W.; Gu, S.; Liu, P.; Zhang, Z.; Wang, S."

作者地址："[Xu, R-H.; Huiyan, L.] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Zhao, H.] Sun Yat Sen Univ, Phase I Ward, Canc Ctr, Guangzhou, Peoples R China; [Wei, W.] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China; [Ma, D.] Zhengzhou Univ, Integrated Tradit Chinese & Western Med Oncol Dep, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China; [Yin, X.] Hunan Canc Hosp, Gastroenterol & Urol, Changsha, Peoples R China; [Ni, Y.] Shanxi Prov Hosp Tradit Chinese Med, Dept Oncol, Taiyuan, Peoples R China; [Wang, Y.] Shanxi Prov Canc Hosp, Digest Dept, Taiyuan, Peoples R China; [Zhang, Y.] Harbin Med Univ, Dept Gastrointestinal Med Oncol, Canc Hosp, Harbin, Peoples R China; [Zhou, J.] Sichuan Canc Hosp, Thorac Oncol, Chengdu, Peoples R China; [Pan, H.] Zhejiang Univ, Sir Run Run Run Shaw Hosp, Dept Med Oncol, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Niu, Z.] Shandong Univ, Digest Dept, Shandong Canc Hosp, Jinan, Shandong, Peoples R China; [Zhang, J.] Shanghai Jiao Tong Univ, Ruijin Hosp, Oncol Dept, Sch Med, Shanghai, Peoples R China; [Ren, H.] Chongqing Med Univ, Hepatol Ctr, Affiliated Hosp 2, Chongqing, Peoples R China; [Kang, M.] Guilin Med Univ, Dept Oncol, Affiliated Hosp, Guilin, Peoples R China; [Jia, W.] USTC, Gen Surg Dept, Affiliated Hosp 1, Anhui Prov Hosp, Hefei, Peoples R China; [Gu, S.] Cent South Univ, Hunan Canc Hosp, Intervent Sect, Changsha, Peoples R China; [Gu, S.] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China; [Liu, P.; Zhang, Z.] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China; [Wang, S.] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shenyang, Peoples R China"

通信作者：　

来源：ANNALS OF ONCOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001087480201356

JCR分区：Q1

影响因子：56.7

年份：2023

卷号：34

期号：　

开始页：S624

结束页：S624

文献类型：Meeting Abstract

关键词：　

摘要：　

基金机构：Jiangsu Hengrui Pharmaceuticals

基金资助正文：Jiangsu Hengrui Pharmaceuticals.